分享帖子
share-weibo分享到微博
share-weibo分享到微信
下载应用
dxy-app
改版反馈
返回顶部

优质经典视频:一个动作终止室上速!

浏览 12.4 万·讨论 300
avatar楼主
发布于 2019-04-04 22:01来自 Android 客户端
只看楼主
icontscicy、齐达内2、曹谦湘潭市中医院 3 位达人点赞

很巧,刚刚阅贴发现同样的是视频园子还有一个,有兴趣可以再参考学习一下,在此感谢@minfeng战友!

帖子链接: 我在丁香园的第一个视频:室上性心动过速急诊复律法    

previewplay video

什么是Valsava动作?

瓦氏动作(Valsalva manoeuvre)是由意大利解剖学家Antonio Maria Valsalva于1704年提出并命名。对于这个名词,我们并不陌生,在书上经常能够看到,但是说起临床应用,只能是“呵呵”了,很多人可能还只是处于纸上谈兵的阶段。

Valsalva试验是令患者行强力闭呼动作,即深吸气后紧闭声门,再用力做呼气动作,呼气时对抗紧闭的会厌,通过增加胸内压来影响血液循环和自主神经功能状态,进而达到诊疗目的的一种临床生理试验。由于在操作上具有简便、实用及无创等优点,Valsava动作在临床上沿用已久。

Valsava动作可以兴奋迷走神经,阻断房室结传导,增加胸腔内压力,减少静脉回心血量,在临床上主要用于:

● 终止阵发性室上性心动过速

● 鉴别心脏杂音的性质和来源:如,通过Valsalva动作,左右心发生的杂音一般均减弱,但肥厚型梗阻性心肌病杂音增强,二尖瓣脱垂患者杂音延长,主动脉瓣狭窄患者杂音减弱,二尖瓣关闭不全患者杂音减弱。

● 心房扑动诊断:心房扑动不容易诊断时,屏气试验可以改变心房扑动的房室传导比例,有利于扑动波暴露。

● 用于右心声学造影:在食道超声检查时,进行右心声学造影,Valsalva动作后3-5个心动周期左心系统显影,提示卵圆孔未闭;超过5个心动周期,考虑肺动静脉分流。

● 对可疑III导联Q波鉴别:III导联Q波较深,不能确定也不能排除下壁心肌梗死,屏气后Q波更小即可排除。

● 诊断呼吸性窦律不齐:呼吸性窦律不齐,屏气后窦性心律不齐基本消失。

● 诊断呼吸性QRS波形态改变:显著的QRS形态及振幅改变,屏气后形态基本一致。

作为一个无创伤性的急诊治疗方法,Valsalva动作虽然可以安全地终止室上性心动过速发作,但是由于做得不到位,实际应用成功率较低只有5%~20%,目前临床应用并不多。多数患者还是不得不到急诊室接受静脉注射抗心律失常药物治疗,或是紧急电复律。

什么是改良的Valsava动作?

为了改变Valsalva动作临床成功率较低的情况,REVERT研究改进了Valsalva动作,结果发表在2015年8月份的《柳叶刀》(Lancet)杂志上。改良的Valsalva动作让患者在半卧位憋气之后立即平卧,并由他人抬高其双腿。

研究显示,改良的Valsalva动作,较传统半卧位可显著提高室上性心动过速的复律成功率。此前仅有17%可成功恢复窦性心律,而改进动作后治疗成功率可达43.5%。因为通过简单调整姿势,就可使患者回心血量增加,从而增加Valsalva动作的成功治疗率,很有临床意义,也避免了一大部分患者不得已注射腺苷而产生的濒死感等不良反应。

改良的Valsalva动作使得憋气动作达到了一个标准,相当于产生40 mmHg的张力,并且通过抬高双腿使得回心血量增加,虽然只是简单的改进,却使得几乎50%的患者达到复律。

来看看两种方法的区别:

Valsalva动作:

(1)保持45°半卧位不变;

(2)用力吹气15秒,在40 mmHg的压力水平下维持15秒,操作者以口头指令帮助患者达到目标压力并维持足够的时间;

(3)等待60秒,复测心电图。

改良的Valsalva动作:

(1)45°半卧位,用力吹气15秒钟并推开10ml的注射器(相当于产生40 mmHg的张力);

(2)吹气结束后立即仰卧,同时助手举起患者双腿至45°-90°,维持15秒;

(3)1 5 秒后回到半卧位,在半卧位保持45秒后复查心电图。

注意:Valsalva动作时间不可过长,不然会导致脑血流和冠脉血流的减少。

img

专题临床干货集锦

851 条内容 · 3.9 万人关注

图图的师兄a 编辑于 2019-04-06 13:25


家兔浦肯野纤维动作电位

全部讨论(300)

avatar
发布于 2019-04-05 18:46
quality reply

确实是几乎零成本的好方法,有2个问题1:有啥不良反应或危险没?;2、复率后能维持多久?复发几率多高?如果复发,再次使用有效率?


彭雪梅:临床常见心律失常处理对策
avatar
发布于 2019-04-04 22:46
quality reply

下面是2015年在柳叶刀发表的一片文章,上面描述了瓦式动作终止室上速的方法,并附带视频,有兴趣的可以看看!!!

Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial

Summary

Background

The Valsalva manoeuvre is an internationally recommended treatment for supraventricular tachycardia, but cardioversion is rare in practice (5–20%), necessitating the use of other treatments including adenosine, which patients often find unpleasant. We assessed whether a postural modification to the Valsalva manoeuvre could improve its effectiveness.

Methods

We did a randomised controlled, parallel-group trial at emergency departments in England. We randomly allocated adults presenting with supraventricular tachycardia (excluding atrial fibrillation and flutter) in a 1:1 ratio to undergo a modified Valsalva manoeuvre (done semi-recumbent with supine repositioning and passive leg raise immediately after the Valsalva strain), or a standard semi-recumbent Valsalva manoeuvre. A 40 mm Hg pressure, 15 s standardised strain was used in both groups. Randomisation, stratified by centre, was done centrally and independently, with allocation with serially numbered, opaque, sealed, tamper-evident envelopes. Patients and treating clinicians were not masked to allocation. The primary outcome was return to sinus rhythm at 1 min after intervention, determined by the treating clinician and electrocardiogram and confirmed by an investigator masked to treatment allocation. This study is registered with Current Controlled Trials (ISRCTN67937027).

Findings

We enrolled 433 participants between Jan 11, 2013, and Dec 29, 2014. Excluding second attendance by five participants, 214 participants in each group were included in the intention-to-treat analysis. 37 (17%) of 214 participants assigned to standard Valsalva manoeuvre achieved sinus rhythm compared with 93 (43%) of 214 in the modified Valsalva manoeuvre group (adjusted odds ratio 3·7 (95% CI 2·3–5·8; p<0·0001). We recorded no serious adverse events.

Interpretation

In patients with supraventricular tachycardia, a modified Valsalva manoeuvre with leg elevation and supine positioning at the end of the strain should be considered as a routine first treatment, and can be taught to patients.

Funding

National Institute for Health Research.

Introduction

The Valsalva manoeuvre is a safe and internationally recommended first-line emergency treatment for supraventricular tachycardia, a common and ubiquitous group of cardiac arrhythmias.

 However, cardioversion is rarely successful in clinical practice (5–20%), and patients who remain in supraventricular tachycardia are usually treated with intravenous adenosine. Adenosine causes transient asystole and is associated with substantial side-effects: many patients report a sense of impending doom or feel that they are about to die and find this very unpleasant and frightening.

Modifications to increase relaxation phase venous return and vagal stimulation, including supine positioning with leg elevation immediately after the Valsalva strain (the modified Valsalva manoeuvre), might improve the Valsalva manoeuvre's effectiveness, but have not been assessed in controlled trials with patients presenting with acute supraventricular tachycardia.

 An improvement in the success rate of the Valsalva manoeuvre with a simple, safe, and cost-free modification to patient positioning during the manoeuvre would be an important finding, with benefits for patients and health-care providers worldwide, including regions with few health-care resources.

We did a randomised controlled trial (REVERT) to assess whether a modified Valsalva manoeuvre is more effective than a standard Valsalva manoeuvre at restoring sinus rhythm in patients presenting to hospital with supraventricular tachycardia.

Methods

 Study design and participants

We did this pragmatic, randomised, multicentre parallel group trial in ten emergency departments (two teaching hospitals, eight district general hospitals) in southwest England between Jan 1, 2013, and April 30, 2015. The study was run according to a previously described design,through the Peninsula Clinical Trials Unit at Plymouth University, overseen by an independently chaired trial steering committee.

Research in context

Evidence before this study

We searched MEDLINE, Embase, and CINAHL databases for “Valsalva manoeuvre AND supraventricular tachycardia OR re-entrant tachycardia” using MeSH terms and appropriate variations in 2009, before our study began. We excluded studies of children and those that did not describe the Valsalva manoeuvre. 269 citations were reviewed and six studies were relevant to our research question. We also searched the Cochrane and Bandolier databases using the terms “Valsalva” and “supraventricular tachycardia”, and found no relevant articles. A repeat of the search on April 15, 2015 identified a Cochrane Review (updated from 2013), which included three studies, all of which we had reviewed in 2009.

Of the six studies reviewed, only two directly assessed the effect of posture on Valsalva manoeuvre effectiveness. One compared supine and sitting Valsalva manoeuvre for induced supraventricular tachycardia in an electrophysiology laboratory and the other was an uncontrolled trial of Trendelenberg Valsalva manoeuvre for acute supraventricular tachycardia in an emergency department. No randomised controlled trials compared posture for the management of patients with acute supraventricular tachycardia presenting to hospital.

Added value of this study

This study is the first randomised controlled trial to assess the effect of posture modification to the Valsalva manoeuvre in patients presenting with acute supraventricular tachycardia. A standard strain was used to ensure that the Valsalva manoeuvre, other than the change in posture, was the same for both groups. This study was pragmatic, done in a clinical setting to which patients often present, and used usual treating staff. The proportion of cardioversions should therefore occur in normal practice if the modified technique is adopted, and serves as a baseline against which future studies can be compared.

Implications of all the available evidence

In patients presenting with stable supraventricular tachycardia, a 15 s, 40 mm Hg Valsalva strain in the semi-recumbent position should be followed immediately by supine repositioning and passive leg elevation. It should be repeated once if unsuccessful. Consideration should be given to enabling patients to do this themselves, and for making this a standard initial treatment.

Patients with suspected supraventricular tachycardia (at emergency department triage or initial assessment) were screened for participation, including routine 12-lead electrocardiogram (ECG), before any emergency arrhythmia treatment. We included patients aged older than 18 years presenting to the emergency department with supraventricular tachycardia (regular, narrow complex tachycardia with QRS duration <0·12 s on ECG). We excluded unstable patients with systolic blood pressure less than 90 mm Hg or an indication for immediate cardioversion and those in atrial fibrillation or flutter. Other exclusion criteria were suspected atrial flutter requiring a trial of adenosine, the presence of any contraindication to Valsalva manoeuvre (aortic stenosis, recent myocardial infarction, glaucoma, retinopathy), inability to performing a Valsalva manoeuvre, to lie flat, or have legs lifted (or any reason identified by the patient as to why this manoeuvre would cause discomfort or pain), third trimester pregnancy, or previous inclusion in this study.

The study was approved by the South West—Exeter Research Ethics Committee, and done in accordance with Good Clinical Practice principles. All participants provided written informed consent.

 Randomisation and masking 

Participants were randomly assigned (1:1) to a standard Valsalva manoeuvre (control) or modified Valsalva manoeuvre (intervention) as their first treatment with permuted blocks of size two, four, and six, stratified by centre. Allocations were prepared by an independent statistician and placed in serially numbered, opaque, sealed, tamper-evident envelopes by the clinical trials unit.

Treatment was determined by selecting the next randomisation envelope in sequence and was checked against a randomisation log. The recruiting doctor or nurse had to sign and date the envelope across the seal to confirm that the next available and lowest numbered envelope of the batch had been taken and that it had not been opened previously. Correct and sequential use of envelopes as described in the protocol was strictly audited by the site research team and clinical trials unit. This process enabled effective randomisation and immediate availability of trial paperwork, without the need for telephone or computer use, and was specifically chosen to aid successful consecutive recruitment in the emergency department.

Treating clinicians could not practically be masked to the allocation. Trial paperwork and explanations disguised from participants which was the study intervention and which was the control by use of descriptive terms for each Valsalva manoeuvre. All analyses were done by investigators masked to treatment allocation.

 Procedures

For both groups, the Valsalva manoeuvre strain was standardised to a pressure of 40 mm Hg sustained for 15 s by forced expiration measured by aneroid manometer with the target pressure marked and visible to the participant and treating team. Standardised verbal instructions were used to help participants to achieve target pressure and strain duration.

The control manoeuvre was termed the “stay sitting Valsalva” to reduce bias. Participants, positioned semi-recumbent (at 45°) on a trolley, were directed to perform the standardised strain and remained in the same position for 60 s before reassessment of cardiac rhythm, initially by 3-lead ECG. A training video was given to all participating centres.

The modified Valsalva manoeuvre (intervention) was termed “lying down with leg lift Valsalva” (video). Participants performed the standardised strain in the same semi-recumbent position but immediately at the end of the strain, were laid flat and had their legs raised by a member of staff to 45° for 15 s. Participants were then returned to the semi-recumbent position for a further 45 s before re-assessment of cardiac rhythm, initially by 3-lead ECG.

If sinus rhythm was not restored, participants were invited to undertake one further attempt at the allocated Valsalva manoeuvre. A 12-lead ECG was recorded if return to sinus rhythm was achieved at 1 min after Valsalva manoeuvre, and 1 min after the second manoeuvre even if unsuccessful.

Treating clinicians or the research nurses recorded whether the allocated Valsalva manoeuvre was performed, the peak pressure and the total duration of strain achieved, whether sinus rhythm was restored, and any adverse events.

Subsequent management was entirely at the discretion of the treating clinical team according to standard guidelines. At discharge, participants were given written instructions on how to perform both types of Valsalva manoeuvre themselves using a 10 mL syringe  and provided with the website address of the Arrhythmia Alliance, a patient support charity.

Participants were followed up until discharge from the emergency department. Participant demographics, details of past medical history, subsequent emergency department treatment, and time spent in the emergency department were also recorded. We retrospectively screened all emergency department attendances during the trial period to get local feedback of missed, but potentially eligible patients, and to more fully describe the population from which our participants were recruited.

 Outcomes

The primary outcome was the presence of sinus rhythm as recorded by the treating clinician 1 min after Valsalva manoeuvre and confirmed by ECG in the intention-to-treat population. All trial ECGs were retrospectively assessed by an independent cardiologist, masked to treatment allocation. Disagreement with the treating clinician's ECG interpretation was arbitrated by an independent electrophysiologist masked to treatment allocation. Primary outcome data were corroborated by an independently chaired endpoint committee when necessary. Every attempt was made to retrieve missing data. In cases where the post-Valsalva manoeuvre ECG was missing, primary outcome was confirmed by endpoint committee. Such cases were reviewed in detail with all available evidence to confirm the primary outcome. For the purpose of the intention-to-treat analysis only, spontaneous cardioversion that occurred after randomisation but before intervention, was considered a treatment success, but all such cases were also reviewed by the endpoint committee.

Secondary outcomes were the use of adenosine, the use of any emergency treatment for supraventricular tachycardia (including adenosine), the need and reason for admission to hospital, the length of time participants spent in the emergency department, and adverse events. We also compared the adequacy of the Valsalva manoeuvre strain. To enable a per-protocol analysis and description of the cohort, participants' presenting arrhythmias were also retrospectively classified by the clinicians' final diagnoses and expert ECG reports with recourse to the arbiter when there was disagreement.

 Statistical analysis

To calculate the required sample size, we estimated that the standard Valsalva manoeuvre would cause cardioversion in 15% of patients with supraventricular tachycardia on the basis of local audit data and previous studies.

 We powered our study to be able to detect at least a 12% absolute improvement with the modified Valsalva manoeuvre, using the available evidence and the minimum improvement we thought would effect a change in practice. We estimated that this difference would require 186 patients per group (assuming a two-tailed test of statistical significance with an α of 0·05 and power of 0·8), and a 22 month recruitment period across ten centres.

We expected that some patients would spontaneously revert to sinus rhythm between randomisation and intervention. We closely monitored rates of spontaneous cardioversion, recruitment, and emergency department final diagnoses. We recruited ahead of target but noted that 5% of participants had spontaneous cardioversion after randomisation and before intervention, and a higher than expected recruitment of participants with non-eligible tachycardia (mainly atrial flutter). It was therefore decided, with agreement of the steering committee, to continue recruiting until the end of the planned recruitment period to maximise the number of participants with eligible supraventricular tachycardia, to meet our initial sample size assumptions and increase trial precision.

There was no opportunity for crossover of trial treatments except in the case of error, and participants were analysed according to intention to treat. In accordance with the statistical analysis plan, second episode data from patients recruited in error for a second time were excluded.

We report baseline data descriptively by group. We compared binary outcomes (including the primary outcome) using mixed effects logistic regression with allocation group as a fixed effect and centre as a random effect. We analysed time spent in the emergency department using Cox proportional hazards regression with a shared frailty model (for centre).

We also did a per-protocol analysis excluding participants who did not undertake at least one trial Valsalva manoeuvre and those with trial ineligible tachycardias (protocol violations). These patients were identified by a final emergency department diagnosis of ineligible tachycardia (atrial flutter, atrial fibrillation, sinus tachycardia, or broad complex tachycardia) or by agreement of expert ECG reviewer and arbiter that the pre-intervention ECG showed one of these excluded arrhythmias.

The trial had no separate data and safety monitoring committee; however, adverse event data and overall cardioversion rates were monitored by the steering committee to ensure safety and non-futility. We did the statistical analyses with Stata (version 14.0).

The study is registered with Current Controlled Trials, ISRCTN67937027.

 Role of the funding source

The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and final responsibility for the decision to submit for publication.

Results

Between Jan 11, 2013, and Dec 29, 2014, 1170 patients attended participating sites with suspected supraventricular tachycardias and of these, 711 patients were screened. We randomly assigned 433 participants, 216 to receive a standard Valsalva manoeuvre and 217 to receive the modified Valsalva manoeuvre (figure). 164 different clinicians delivered the intervention. Data for the second attendance from five patients who were recruited twice in error were omitted from the analyses, leaving 214 in each group. Spontaneous cardioversion after randomisation and before intervention occurred in nine (4%) of 214 participants in the standard group and 12 (6%) of 214 in the modified Valsalva manoeuvre group. Of the 428 participants included in the primary analysis, 205 attempted at least one standard Valsalva manoeuvre and 201 at least one modified Valsalva manoeuvre according to allocation. 179 participants in the standard Valsalva manoeuvre group and 131 in the modified Valsalva manoeuvre group who remained in supraventricular tachycardias attempted a second manoeuvre as allocated.

Discussion

We have shown that a simple, cost-free, well-tolerated postural modification to the standard Valsalva manoeuvre is highly effective, returning more than 40% of patients to sinus rhythm compared with 17% with a standard Valsalva manoeuvre. This difference resulted in a substantial reduction in the number of patients needing other emergency treatments, particularly adenosine. Fewer patients treated with the modified Valsalva manoeuvre needed further emergency department treatment, compared with the standard Valsalva manoeuvre.

We did not detect any time saving or reduced need for hospital admission. Most treatments for supraventricular tachycardia take little time and take up only a small proportion of the total time spent in the emergency department. Likewise, the need for hospital admission is usually determined by the presence of concurrent medical conditions and not for the supraventricular tachycardia per se, which was similar in each group.

A higher proportion of patients had cardioversion in our study than in most observational studies, but the proportion in the control group was similar to that on which we based our sample size and within the range in routine practice. By contrast, the proportion of patients who cardioverted in the modified Valsalva manoeuvre group was substantially higher than that reported in other studies of emergency supraventricular tachycardia vagal treatments, and greater than the 31% reported by Walker and Cutting with a Trendelenberg (supine with head down incline) Valsalva manoeuvre. We believe that there are sound physiological reasons for this difference, with the sequence and timing of the strain and changes to position all important to the success of our particular modification.

We compared a modified Valsalva manoeuvre with the Valsalva manoeuvre most commonly used in routine practice in this setting.Although a supine Valsalva manoeuvre achieves greater vagal tone in healthy patients or those with induced supraventricular tachycardia,patients are routinely assessed in a semirecumbent position and there might be benefits from starting the Valsalva manoeuvre in this position (augmenting the initial fall in venous return on straining) before maximising venous return in the relaxation phase (Valsalva stage 3) through supine position and passive leg lift.

Treating clinicians could not be masked to treatment allocation but we used strict allocation concealment and standardised instructions, and disguised from participants which allocation was the intervention and which was control. Subsequent emergency department treatment was unlikely to be influenced by knowledge of trial allocation because patients would not conceivably have been left in supraventricular teachycardia without treatment or treated with adenosine when in sinus rhythm. Strain data confirmed the equivalence of the Valsalva manoeuvre strain effort in both groups.

We recruited a higher proportion of patients with non-eligible supraventricular tachycardia (mainly atrial flutter) than expected, as a result of the difficulty of distinguishing such rhythms from re-entrant supraventricular tachycardia in an emergency department. Improving the detection and exclusion of these rhythms might further improve the efficacy of the modified Valsalva manoeuvre, as suggested by the per-protocol analysis. We did not assess the relative frequency of re-entrant supraventricular tachycardia subtypes—eg, atrioventricular nodal re-entry tachycardia and atrioventricular re-entry tachycardia. This distinction is not routinely, accurately, or reliably made at presentation and does not affect initial hospital management or preclude use of a Valsalva manoeuvre as first-line treatment.

Future work should assess the implementation and dissemination of this technique and its performance in routine practice. Studies comparing it with the fully supine Valsalva manoeuvre in both patients and healthy volunteers should also be considered.

An improved Valsalva manoeuvre that is successful in 50% of cases has potential benefits for patients with supraventricular tachycardia worldwide. Our study was pragmatic and done in an environment in which these patients are often treated, but used a modification that can be done anywhere, including community and resource-poor settings, without specialist equipment. We used a manometer to ensure a consistent and measurable 40 mm Hg strain, but a 10 mL syringe blown to just move the plunger generates a similar pressure.

We did not identify any disadvantages of using the modified Valsalva manoeuvre technique. As long as individuals can safely undertake a Valsalva strain and be repositioned as described, this manoeuvre can be used as the routine initial treatment for episodes of supraventricular tachycardia regardless of location. The technique could prevent many patients from being treated with drugs or even seeking health care. Clinicians who encounter this condition should consider learning the technique and teaching it to patients after a first episode of supraventricular tachycardia.



低血压研究现状及对策
avatar
发布于 2019-04-09 10:07来自 Android 客户端
quality reply
上次科里收了一个脑出血的患者,男,65岁,既往心脏支架植入4枚。心电监护提示室上速,下意识的给予按压颈动脉,按压几秒后未见恢复,考虑患者往往有颈动脉斑块,为防因为按压导致脱落改为按压眼眶。约半分钟后复律。 其实在八版内科学里面对于室上速也是推荐刺激迷走神经反应改善。对于迷走神经反应的诱发还是有一定风险的(高龄患者便秘时用力解大便就是valsava动作),不要忘了裘法祖老先生就是解大便去世的。 那么敢不敢做,就看你了

2012年中华医学会高敏心肌肌钙蛋白在急性冠状动脉综合征中的应用中国专家共识

还有 297 条讨论,登录后查看

X-POWER-BY FNC V0.5.2 FROM ZZ50